|

Tislelizumab+liposomal doxorubicin+ifosfamide Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Fudan University1

Indications

  • Malignant Peripheral Nerve Sheath Tumor (MPNST)1
  • Pleomorphic Liposarcoma1
  • Desmoplastic Small Round Cell Tumor1
  • Angiosarcoma1
  • Leiomyosarcoma1

Other1 trial

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.